Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Researchers in Korea say they found a way to potentially accelerate the development of high-performance organic electrochemical transistor devices with tunable transient responses. Organic mixed ionic-electronic conductors (OMIECs) offer potential bioelectric applications. Researchers at the Gwangju Institute of Science and Technology (GIST) used the transistors as platforms for testing the molecular orientation and ion injection directionality-dependent transient properties of OMIECs. Potential applications for OMIECs include computing and bio-fuel cells in addition to bioelectronics. The researchers say that, to ensure a wider acceptance of these materials, there remains a need to diversify their properties and develop techniques for application-specific OMIEC tailoring. They cite a “severe” lack of research on the molecular orientation-dependent transient behaviors of such conductors. The team at GIST, consisting of researchers from both Korea and the UK, set out to bridge the gap in understanding there. Professor Myung-Han Yoon from the GIST School of Materials Science and Engineering led the researchers. They explored the transient behaviors of OMIECs governed by variations in molecular orientation with the help of an organic electrochemical transistor (OECT). “OECTs are known to mimic the computing mechanisms of neurons and synapses in spiking neural networks (SNNs) and are thus considered promising,” said Yoon. “To aid the growing interest in exploring the dynamic behaviors of OECTs at the frequency domain, we focused on an aspect that is often overlooked. We decided to investigate the correlation between backbone planarity-dependent molecular orientation and transient OECT characteristics.” First, they synthesized two new 1,4-dithienylphenylene (DTP)-based OMEICs, DTP-2T and DTP-P, with co-monomer units, 2,2’-bithiophene and phenylene, respectively. According to GIST, the polymers comprised the same ionic and electronic properties. However, by manipulating the polymer backbone planarity, the researchers controlled the dominant molecular orientation of the mixed conductor system. This polymer then successfully helped to fabricate OECT devices. The team found that the polymers showed similar electrochemical properties despite having different molecular orientations. They then changed the ion injection direction when observing a certain current/voltage during the analysis. In the analysis, the researchers saw that ion injection relative to the molecular orientation affected the length of the ion drift pathway. This, in turn, resulted in peculiar transient responses in OECT devices. The team believes it could use its research to facilitate the design and development of advanced organic mixed conductor materials for biomolecular and biosignal sensors. “OECT-based SNN architectures are anticipated to replace current computing systems in the future by increasing computation speed and reducing energy consumption,” Yoon said. “Our findings are expected to facilitate the realization of SNN-based computing systems soon.”